RxDoctor Payments DataLook up a doctor →

Julia Sohn, MD

Allergy & Immunology · Rockville, MDNPI 1689091696

Payments from drug & device makers

$15,721in general payments, 2019–2025

Across 556 payments — averaging $28.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$4K
  • AstraZeneca$3K
  • GSK$2K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Novartis$525
  • Amgen$466
  • plus $4K from 28 others

What the payments were for

  • Consulting fees$1,59910%
  • Speaking & faculty fees$1751%
  • Travel & lodging$410%
  • Food & beverage$13,84688%
  • Education$610%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,721 in reported general payments places this provider in the 80th percentile of 105 allergy & immunology providers in Maryland.

See all allergy & immunology providers in Maryland

Medicare billing

Part B allowed, 2024
$140,473
Medicare patients
181
Services billed
4,913

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$63,401
Breo ElliptaFluticasone/Vilanterol19$14,634
Azelastine-FluticasoneAzelastine/Fluticasone27$5,175
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$2,515
Azelastine Hcl55$2,320
Montelukast Sodium110$1,912
Desloratadine11$938
Fluticasone Propionate27$590
Olopatadine Hcl11$590
Ipratropium Bromide25$581
Albuterol Sulfate HfaAlbuterol Sulfate27$511
Levocetirizine Dihydrochloride12$198
Prednisone11$42

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$2,287$78,03562 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 105 allergy & immunology providers in Maryland.

Other allergy & immunology in Rockville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →